With currently more than 90 distinct drugs in research and development, MorphoSys has one of the broadest antibody pipelines in the biotechnology industry. 22 different therapeutic antibodies are already being evaluated in clinical trials and tested as options for treatment of severe and in many cases life-threatening diseases. The Company’s product pipeline comprises both partnered and proprietary antibody therapeutic development programs, as shown below:


Program Partner Indication Phase 1 Phase 2 Phase 3 Market
MOR103 GlaxoSmithKline Rheumatoid arthritis
Multiple sclerosis
MOR208 Acute lymphoblastic leukemia
Chronic lymphocytic leukemia
MOR202 Celgene Multiple myeloma
Bimagrumab Novartis Sporadic inclusion body myositis
Cachexia (cancer)
Cachexia (COPD)
Muscle atrophy after hip fracture surgery
Gantenerumab Roche Mild Alzheimer's disease
AD, genetically predisposed patients
Alzheimer's disease, Japanese patients
Bioavailability study
Guselkumab Janssen/J&J Psoriasis (NAVIGATE)
Psoriasis (VOYAGE 1)
Psoriasis (VOYAGE 2)
Rheumatoid arthritis
Palmoplantar pustulosis
Psoriatic Arthritis
BHQ880 Novartis Multiple myeloma (renal insufficiency)
Smoldering multiple myeloma
CNTO3157 Janssen/J&J Asthma
Safety / pharmacokinetics
CNTO6785 Janssen/J&J Rheumatoid arthritis
Chronic obstructive pulmonary disease (COPD)
LFG316 Novartis Wet AMD
Geographic atrophy
Multifocal choroiditis and panuveitis (MCP)
LJM716 Novartis Esophageal cancer (ESCC)
HER2-positive cancer
HER2-positive cancer, + trastuzumab
HER2-positive cancer, + BYL719 + trastuzumab
Solid tumors
NOV–3 Novartis Not disclosed
Tarextumab OncoMed Pancreatic cancer
Small cell lung cancer
Solid tumors
VAY736 Novartis Pemphigus vulgaris
Primary Sjörgen's syndrome
Relapsing-remitting MS
Anetumab Ravtansine Bayer HealthCare Solid tumors
BI-836845 Boehringer Ingelheim Non-small cell lung cancer (NSCLC)
Prostate cancer (CRPC), + enzalutamide
Breast cancer
Solid tumors
Cancer, Japanese patients
NOV-7 Novartis Eye disease
NOV-8 Novartis Inflammation
NOV-9 Novartis Eye disease
NOV-10 Novartis Oncology
PF-05082566 Pfizer Solid tumors, non-Hodgkin-lymphoma
Solid tumors, + PD-1 inhibitor MK-3475
Vantictumab OncoMed Solid tumors
Breast cancer
Pancreatic cancer
Non-small cell lung cancer (NSCLC)

Additionally, MorphoSys currently has various proprietary and partnered programs in the Discovery or Pre-clinical phase (December 31, 2014: 45 programs in Discovery, 27 programs in Pre-clinic)

  • Partnered Programs
  • Proprietary Program

Clinical Trials

MorphoSys is currently involved in several active clinical trials.